Summary of Jasper Therapeutics FY Conference Call Company Overview - **Company**: Jasper Therapeutics (NasdaqCM:JSPR) - **Industry**: Biotechnology - **Focus**: Clinical stage biotech company specializing in monoclonal antibodies, particularly briquilimab (BRIC) for chronic spontaneous urticaria (CSU) and asthma [3][2] Key Findings and Updates Chronic Spontaneous Urticaria (CSU) - **Investigation Results**: An internal investigation was initiated after unexpected results in cohorts eight and nine, where 10 out of 13 patients showed no clinical response. The investigation concluded that the drug product was not at fault; rather, many patients did not have mast cell-mediated CSU [4][5][6] - **Misdiagnosis Rate**: It was noted that 20%-25% of CSU patients may be misdiagnosed, emphasizing the challenges in clinical diagnosis without biomarkers [7][8] - **New Measures**: To prevent future misdiagnoses, additional measures have been implemented, including a third clinical reviewer and requiring a minimum six-month history of CSU diagnosis for new patients [8][9] Upcoming Data and Expectations - **Data Milestones**: Significant data is expected in the first half of Q1, including results from new patients in cohorts eight and nine. A complete response rate similar to Celldex's 50% would be considered a success [10][11] - **Safety Profile**: The safety profile of briquilimab is a primary focus, with positive results noted in previous dosing [11][12] Open Label Extension (OLE) Study - **Patient Enrollment**: Most patients from the Beacon study opted to roll over into the OLE, indicating perceived benefits from the treatment. Data from 35-40 patients in the OLE will be available early next year [17][18] Phase 2B Study Design - **Study Structure**: The upcoming phase 2B study will be a three-arm trial with two dosing regimens and a placebo arm, estimated to cost $40-$50 million [19][30] Asthma Research - **Allergen Challenge Study**: The asthma study involved a classic design measuring FEV1 and eosinophil levels post-allergen challenge. Initial findings showed a significant reduction in eosinophils in treated patients [20][24] - **Future Studies**: Discussions are ongoing regarding the next steps in asthma research, including potential multi-dose studies and patient selection criteria [27][28] Financial Overview - **Capital Raise**: Jasper Therapeutics raised $30 million, providing a cash runway into Q3 of the following year, allowing for the initiation of the phase 2B study [30][31] Additional Insights - **Expert Consultation**: The company plans to consult with experts in asthma drug development to refine patient selection and study design for future trials [28][29] - **Focus on Eosinophils**: The reduction of eosinophils in the asthma study suggests potential implications for both T2 high and T2 low patient groups [28]